{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-034187","form_type":"8-K","ticker":"SHC","cik":"0001822479","company_name":"Sotera Health Co","filed_at":"2023-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.801967+00:00","generated_at":"2026-06-19T16:34:04.795181+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sotera Health reaffirms 2022 guidance, plans $425M Term Loan B to fund $408M EO litigation settlement","bullets":["Reaffirms 2022 net revenue guidance of $995M-$1.005B and Adjusted EBITDA of $500M-$510M.","Expects 2022 net loss of $226M-$236M including a $408M legal reserve for ethylene oxide settlement.","Plans $425M Term Loan B facility to fund $408M EO settlement, pay down revolver, and boost liquidity.","Preliminary estimates subject to completion of year-end closing; final results expected February 28, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-034187","json":"https://secwatch.observer/filing/0001193125-23-034187.json","markdown":"https://secwatch.observer/filing/0001193125-23-034187.md","text":"https://secwatch.observer/filing/0001193125-23-034187.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/0001193125-23-034187-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/d428886d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T16:34:04.795181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dd8683dec8fcc3366fdca8716522fef18f2ae41","claim":"Sotera Health Co reported the year ended December 31, 2022 results: revenue $995 million to $1.005 billion, net income $226 million to $236 million. Guidance reaffirmed.","evidence_excerpt":"The Company is reaffirming its expectation that 2022 full-year net revenues will be within the previously announced guidance range of $995 million to $1.005 billion. The Company also is announcing that the 2022 full-year net loss is expected to be in a range of $226 million to $236 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822479/000119312523034187/0001193125-23-034187-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$995 million to $1.005 billion"},{"label":"Net income","value":"$226 million to $236 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}